Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...
Philadelphia-based Penn Medicine has developed a generative AI tool designed to help clinicians quickly identify and ...
The addition of agentic AI capital planning further strengthens TRIMEDX-AIQ as the intelligence layer powering smarter clinical asset decisions, helping systems reduce waste, optimize utilization, and ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with ...
UB is tapping AI’s incredible power to address global challenges by advancing education, research and outreach.
Indianapolis, Indiana, Dec. 15, 2025 (GLOBE NEWSWIRE) -- TRIMEDX today announced the launch of TRIMEDX-AIQ™ , a breakthrough AI intelligence offering that sets a new standard for clinical asset ...
Alzheimer’s Disease Analysis Model Generation 1 (ADAM-1) is a multi-agent reasoning large language model (LLM) framework designed to integrate and analyze multimodal data, including microbiome ...